![clone drone in the danger zone igg clone drone in the danger zone igg](https://iigg-games.net/gimgs/wont-you-be-my-laser/w330/wont-you-be-my-laser-free-download.jpg)
Although dexamethasone (DXM) possesses remarkable anti-inflammatory action, its use also leads to severe adverse effects, mainly due to immunosuppression.
![clone drone in the danger zone igg clone drone in the danger zone igg](https://i2.wp.com/www.oyunindir.club/wp-content/uploads/2015/10/castle-clash1.jpg)
During recent decades, synthetic glucocorticoids have been widely used for the treatment of liver diseases. Potential approaches to inhibit the fibrotic process mainly include strategies to suppress inflammation, by reducing viral load and downregulating liver NPC-driven immune response. In these patients, persistent inflammation has been described as the main cause of hepatic fibrosis and cirrhosis. Taken together, nanostructured lipid carriers may constitute a reliable platform for the delivery of DXM to treat pathologies associated with chronic liver inflammation.Ĭhronic liver inflammation is a characteristic of pathologies, such as chronic viral hepatitis and autoimmune hepatitis. Released DXM preserved its pharmacological activity, as evidenced by inducing robust anti-inflammatory responses in NPCs. This nano-formulation proved to be stable over time, did not interact in vitro with plasma opsonins, and was well tolerated by primary non-parenchymal liver cells (NPCs). Here we describe a nanostructured lipid carrier developed to efficiently encapsulate and release DXM. The use of nanocarriers for encapsulation and sustained release of glucocorticoids to liver cells could provide a solution to prevent severe side effects associated with systemic delivery as the conventional treatment regime. Among the strategies to prevent liver failure, dexamethasone (DXM) has been widely used to suppress inflammatory responses. Liver inflammation represents a major clinical problem in a wide range of pathologies.